<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481336</url>
  </required_header>
  <id_info>
    <org_study_id>A-ER-103-395</org_study_id>
    <nct_id>NCT02481336</nct_id>
  </id_info>
  <brief_title>To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity</brief_title>
  <official_title>Integrating Clinical and Genomic Profiles for Prediction and Prevention of Chemotherapy-induced Neuropathy Via Big Bio-Data Analytics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the risk prediction of chemotherapy-induced peripheral neuropathy (CIPN) by the&#xD;
      clinical bioinformatics and genomic profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational, cohort study, monitoring the chemotherapy-induced&#xD;
      peripheral neurotoxicity by traditional clinical scales, neurological examinations, and&#xD;
      semi-quantitative assessments. Moreover, all the genetic changes will be analyzed by next&#xD;
      generation sequencing and we will try to identify relevant variants in individuals who suffer&#xD;
      from chemotherapy-induced neurotoxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events occurring after chemotherapy based on genomic profiling</measure>
    <time_frame>up to 2 years after chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in quality-of-life measured by EORTC CIPN20</measure>
    <time_frame>up to 2 years after chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality-of-life measured by EQ-5D-3L</measure>
    <time_frame>up to 2 years after chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in nerve conduction velocity (NCV)</measure>
    <time_frame>up to 2 years after chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in quantitative sensory test (QST)</measure>
    <time_frame>up to 2 years after chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in nerve excitability test (NET)</measure>
    <time_frame>up to 2 years after chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>up to 5 years after chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 5 years after chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Neurotoxicity Syndromes</condition>
  <arm_group>
    <arm_group_label>Cancer patients receiving chemotherapy</arm_group_label>
    <description>Stage I-IV ovarian cancer receiving chemotherapy Paclitaxel/Carboplatin&#xD;
Stage II-IV endometrial cancer receiving chemotherapy Paclitaxel/Carboplatin&#xD;
Stage III &amp; high risk stage II colorectal cancer receiving chemotherapy with mFOLFOX&#xD;
Questionnaires&#xD;
Peripheral nervous system examination&#xD;
Whole Genome Sequence</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>EORTC CIPN20 and EQ-5D-3L</description>
    <arm_group_label>Cancer patients receiving chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral nervous system examination</intervention_name>
    <description>nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)</description>
    <arm_group_label>Cancer patients receiving chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Whole Genome Sequence</intervention_name>
    <description>Genetic Test : 10 mL blood will be collected in Blood Sample Collection</description>
    <arm_group_label>Cancer patients receiving chemotherapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Sample Collection with DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Total 300 cancer patients will be enrolled in National Cheng Kung University Hospital from&#xD;
        March, 2015 to March, 2017. The subjects are stage I-IV ovarian cancer patients receiving&#xD;
        chemotherapy Paclitaxel/Carboplatin, stage II-IV endometrial cancer patients receiving&#xD;
        chemotherapy Paclitaxel/Carboplatin, stage III &amp; high risk stage II colorectal cancer&#xD;
        patients receiving chemotherapy with mFOLFOX.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed epithelial ovarian cancer, endometrial cancer or&#xD;
             adenocarcinoma of colon or rectum&#xD;
&#xD;
          2. Pathological stage I~IV for ovarian cancer, stage II~IV endometrial cancer or stage&#xD;
             III &amp; high risk stage II for colorectal cancer&#xD;
&#xD;
          3. Scheduled to receive adjuvant Paclitaxel/Carboplatin for ovarian or endometrial&#xD;
             cancer, or mFOLFOX6 for colorectal cancer&#xD;
&#xD;
          4. Age ≥ 20 years old&#xD;
&#xD;
          5. ECOG Performance status 0-1&#xD;
&#xD;
          6. Adequate organ function&#xD;
&#xD;
             Bone marrow:&#xD;
&#xD;
             Absolute neutrophil count (ANC) ≥ 1.5 x 109/L WBC ≥ 3.0 x 109/L Platelet count ≥ 100 x&#xD;
             109/L Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
             Hepatic:&#xD;
&#xD;
             Total bilirubin level ≤ 1.0 x UNL AST and ALT ≤ 3.0 x UNL&#xD;
&#xD;
             Renal:&#xD;
&#xD;
             Creatinine level ≤ 1.5 mg/dL in men, ≤1.4 mg/dL in women; or Estimated CCr ≥ 60 mL/min&#xD;
             (CCr is estimated by Cockcroft-Gault formula, as appendix III).&#xD;
&#xD;
          7. Negative pregnancy test for women of childbearing potential only&#xD;
&#xD;
          8. Patient willing to provide blood sample for research purposes&#xD;
&#xD;
          9. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with neurotoxic chemotherapy, such as oxaliplatin, cisplatin,&#xD;
             carboplatin, taxanes or vinca alkaloids&#xD;
&#xD;
          2. Receiving chemotherapy within 6 months&#xD;
&#xD;
          3. History of allergy to 5-FU or LV&#xD;
&#xD;
          4. Pre-existing peripheral neuropathy of any grade&#xD;
&#xD;
          5. A family history of a genetic or familial neuropathy&#xD;
&#xD;
          6. Active uncontrolled infection&#xD;
&#xD;
          7. Significant medical diseases, such as unstable angina, acute or recent myocardial&#xD;
             infarction (&lt;6 months before enrollment), COPD with frequent exacerbation,&#xD;
             uncontrolled hypertension, ore cent CVA (&lt;6 months before enrollment)&#xD;
&#xD;
          8. Poor compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng-Ru Shen, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cheng Kung University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng-Ru Shen, PHD</last_name>
    <phone>886-6-2353535</phone>
    <phone_ext>5505</phone_ext>
    <email>mrshen@mail.ncku.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng-Ru Shen, PHD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <keyword>Peripheral Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

